Clinical trialPhase 2Terminated
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells
- Outcome
- Stopped early. Results posted; single-arm, no comparisonFutility analysis determined closure (Efficacy or futility)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 7 December 2017
- Ended
- 28 August 2023
- Enrollment
- 31 participants
- Sites
- 1
- Primary outcomes
- Relapse Rate
- Sponsor type
- Academic / other
- Results posted
- 2 April 2024
- Last update
- 4 July 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 4 July 2025
- Primary outcome
- Relapse RateTreatment (Fludarabine, Cyclophosphamide, TBI, PBSCT): 14 of 31Values: ParticipantsTime frame: At 1 yearNo analysis posted for this outcome (outcome 1)
- Participants
- Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT): 31 started, 29 completed
- Serious adverse events
- Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT): 8 of 31Participants with at least one serious adverse event, of those at risk, as posted
7 secondary outcomes
- ANC Engraftment Rate, the Percentage of Participants That Had a Successful Engraftment
- Treatment (Fludarabine, Cyclophosphamid… 84 (66.0 to 95.0), n=31 [percentage of participants, 95% Confidence Interval]
- Platelet Engraftment Rate, the Percentage of Participants That Had a Successful Engraftme…
- Treatment (Fludarabine, Cyclophosphamid… 77 (59 to 90), n=31 [percentage of participants, 95% Confidence Interval]
- Proportion of Participants With Acute Graft Versus Host Disease (GVHD)
- Treatment (Fludarabine, Cyclophosphamid… 0.3226 (0.1668 to 0.5137), n=31 [proportion of participants, 95% Confidence Interval]
- Proportion of Participants With Chronic Graft Versus Host Disease (GVHD)
- Treatment (Fludarabine, Cyclophosphamid… 0.1935 (0.0745 to 0.3747), n=31 [proportion of participants, 95% Confidence Interval]
- OS · Overall Survival
- Treatment (Fludarabine, Cyclophosphamid… 15.7 (7.1 to NA), n=31 [median months, 95% Confidence Interval]
- PFS · Progression Free Survival
- Treatment (Fludarabine, Cyclophosphamid… 15.7 (5.5 to 49.5), n=31 [median months, 95% Confidence Interval]
- Transplant Related Mortality
- Treatment (Fludarabine, Cyclophosphamid… 0.0323 (0.0008 to 0.1670), n=31 [proportion of participants, 95% Confidence Interval]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase II trial studies how well fludarabine phosphate, cyclophosphamide, total body irradiation, and donor stem cell transplant work in treating patients with blood cancer. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient?s immune cells and help destroy any remaining cancer cells.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVES: I. To evaluate the rate of relapse, defined as recurrence of underlying disease or progression of underlying disease, at 1 year in patients who receive haploidentical peripheral blood stem cells (PBSCs) after reduced intensity conditioning and post-transplant cyclophosphamide and tocilizumab (or tocilizumab alternative). SECONDARY OBJECTIVES: I. To evaluate safety including development of acute graft versus host disease (GVHD) and death at 100 days post-transplant, as well as other treatment related toxicities including chronic GVHD, engraftment rate, non-relapse mortality, progression free survival (PFS) at one year, and overall survival (OS) at one year, as compared with historical controls. TERTIARY OBJECTIVES: I. Correlative studies will include chimerism analysis by molecular analysis and evaluation of immune reconstitution by cytomegalovirus (CMV) dextramer analysis using flow cytometry. OUTLINE: Patients receive fludarabine phosphate intravenously (IV) over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo total body irradiation (TBI) on days -1 and peripheral blood stem cell transplantation (PBSCT) on day 0. After completion of study treatment, patients are followed up at 30 and 100 days.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Relapse Rate [At 1 year]. Count Of Participants, Participants. Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT) (n=31): 14.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
ANC Engraftment Rate, the Percentage of Participants That Had a Successful Engraftment [At 1 year post-transplant]. Number, percentage of participants (95% Confidence Interval). Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT) (n=31): 84 (66.0 to 95.0).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Platelet Engraftment Rate, the Percentage of Participants That Had a Successful Engraftment [At 1 year post-transplant]. Number, percentage of participants (95% Confidence Interval). Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT) (n=31): 77 (59 to 90).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Proportion of Participants With Acute Graft Versus Host Disease (GVHD) [At 100 days post-transplant]. Number, proportion of participants (95% Confidence Interval). Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT) (n=31): 0.3226 (0.1668 to 0.5137).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Proportion of Participants With Chronic Graft Versus Host Disease (GVHD) [At 1 year post-transplant]. Number, proportion of participants (95% Confidence Interval). Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT) (n=31): 0.1935 (0.0745 to 0.3747).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival [up to 5 years and 8 months]. Median, months (95% Confidence Interval). Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT) (n=31): 15.7 (7.1 to NA) [Upper limit not reached].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression Free Survival [up to 5 years and 8 months]. Median, months (95% Confidence Interval). Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT) (n=31): 15.7 (5.5 to 49.5).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Transplant Related Mortality [At 1 year post-transplant]. Number, proportion of participants (95% Confidence Interval). Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT) (n=31): 0.0323 (0.0008 to 0.1670).